AMD eye drop enters Phase II

Article

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

ATG3 is a proprietary ophthalmic formulation of mecamylamine, an antagonist of the nicotinic acetylcholine receptor pathway that mediates angiogenesis.

The Phase II study will enrol 330 subjects to be randomized into one of three treatment groups: two different doses of ATG3 administered twice daily, or placebo. All subjects will be monitored over a 48-week period to assess the drug's safety, tolerability and efficacy.

During the Phase I trial, the drug demonstrated good ocular tolerability in 80 subjects and confirmed that systemic exposure following eyedrop administration is minimal, with no systemic side effects. Furthermore, studies in animal models have shown good penetration of the formulation to the retina and choroids, as well as a reduction of new blood vessel growth in the eye.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.